[Form 4] HALOZYME THERAPEUTICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

Officer equity grants and option exercise reported. The reporting person, Cortney Caudill, SVP and Chief Operating Officer, acquired 9,031 shares via an option exercise with an exercise price of $68.98 and was granted 3,625 restricted stock units (RSUs). The option vests 25% on 10/03/2026 then monthly thereafter over the remaining term to 10/03/2035. The RSU award vests 25% on the first anniversary and then in annual 25% installments thereafter. Following these transactions, the reporting person beneficially owns 9,031 option-derived shares and 3,625 RSUs, reported as direct ownership.

Positive

• Officer received equity compensation (9,031 option-derived shares and 3,625 RSUs), aligning management with shareholders
• Multi-year vesting (25% then monthly or annual vesting) supports retention through 10/03/2035
• Options carry a clear exercise price of $68.98, providing transparency on strike exposure

Negative

• None.

Insights

Compensation & Governance Analyst

Grants align the COO with shareholder outcomes while preserving multi-year vesting.

These actions combine an option exercise and an RSU grant that tie a senior officer's pay to long-term equity value. The option has an exercise price of $68.98 and a full contractual term to 10/03/2035, while the RSUs vest over four years with the first 25% cliff after one year.

The primary dependencies are future stock performance and continued service through vesting dates; key items to watch include vesting milestones at 10/03/2026 and annual anniversaries thereafter for the RSUs and option schedule.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caudill Cortney

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$68.98	10/03/2025		A		9,031		10/03/2026(1)	10/03/2035	Common Stock	9,031	$0	9,031	D
Restricted Stock Units	$0	10/03/2025		A		3,625		10/03/2026(2)	(2)	Common Stock	3,625	$0	3,625	D

Explanation of Responses:

1. This option vests one-fourth on such date and then 1/48th monthly thereafter.

2. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

	/s/ James R. Oehler, Attorney-in-Fact	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Halozyme (HALO) report on the Form 4 filed for Cortney Caudill?

The Form 4 shows acquisition of 9,031 shares via option exercise at $68.98 and a grant of 3,625 RSUs to the SVP/COO.

When do the newly reported options and RSUs vest?

The option vests 25% on 10/03/2026 then 1/48th monthly thereafter until 10/03/2035; the RSUs vest 25% on the first anniversary and then annually.

How many shares does Cortney Caudill beneficially own after the transactions?

The report lists 9,031 shares from the option and 3,625 RSUs as directly beneficially owned following the reported transactions.

What is the exercise price of the options reported on the Form 4?

The reported exercise price for the option is $68.98 per share.

Are the disclosed awards direct or indirect ownership?

Both the option-derived shares and the RSUs are reported as direct ownership in the filing.